Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028828 · ClinicalTrials.gov registry record · Phase 2
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study of Hematologic Malignancies and Allogeneic Stem Cell Transplantation, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06028828: Recruiting Phase 2 study of Hematologic Malignancies and Allogeneic Stem Cell Transplantation, sponsored by University of California, Irvine.
NCT06028828 is a Phase 2 study of Hematologic Malignancies and Allogeneic Stem Cell Transplantation that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 60 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06028828, a Phase 2 study of Hematologic Malignancies and Allogeneic Stem Cell Transplantation, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Primary Outcome
PFS is defined as the time from stem cell infusion to time of disease relapse or death from any cause; data for patients who were alive without relapse will be censored at the date of last contact.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- RADIATION Total Body Irradiation
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06028828 shows while recruiting
NCT06028828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Fludarabine is the first listed.
NCT06028828 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06028828 about?
NCT06028828 is a clinical study titled "Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation". This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
What is the current status of trial NCT06028828?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-09-11. Estimated completion is 2027-09.
What conditions does trial NCT06028828 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Allogeneic Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation.
What interventions are being tested in trial NCT06028828?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Total Body Irradiation (RADIATION).
Who is sponsoring clinical trial NCT06028828?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06028828 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06028828's enrollment target sits among peer trials
60 19th of 45 higher than 26 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RECRUITING · Phase 2
-
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RECRUITING · Phase 2
-
IVIG for Infection Prevention After CAR-T-Cell Therapy
RECRUITING · Phase 2
-
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI